FDCDDQ
MCRB icon

Federation des caisses Desjardins du Quebec’s Seres Therapeutics MCRB Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3
Closed -$58 – 2960
2025
Q3 		$58 Buy
+3
New +$48 ﹤0.01% 2825

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's MCRB Position: Q4 2025 in Review

Federation des caisses Desjardins du Quebec sold out of Seres Therapeutics (MCRB) in Q4 2025, closing a stake of 3 shares — an estimated $58 sold.

Federation des caisses Desjardins du Quebec first reported a position in MCRB in Q3 2025 and held it in 1 quarter. The position peaked at $58 in Q3 2025. 36 funds tracked by Wall St. Rank hold MCRB as of Q4 2025.

  • Federation des caisses Desjardins du Quebec reported no remaining Seres Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 3 Seres Therapeutics shares in Q4 2025, an estimated $58.
  • Federation des caisses Desjardins du Quebec first reported a position in Seres Therapeutics in Q3 2025 and held it in 1 quarter.
  • Federation des caisses Desjardins du Quebec's Seres Therapeutics position peaked at $58 in Q3 2025.
  • 36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2025.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2025, filed 12 Feb 2026.